CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • United States
    Entity • The products and services listed on this website are not available in this location.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Trade Sanofi SA - SAN CFD

    95.44
    1.65%
    0.36
    Low: 94.54
    High: 95.76
    Market Trading Hours* (UTC) Open now
    Closes on Wednesday at 15:30

    Mon - Fri: 07:00 - 15:30

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.36
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.019974 %
    Charges from borrowed part ($-0.80)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.019974%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.002248 %
    Charges from borrowed part ($-0.09)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.002248%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency EUR
    Margin 20%
    Stock exchange France
    Commission on trade 0%

    *Information provided by Capital.com

    Sanofi SA ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 94.07
    Open* 94.54
    1-Year Change* -5.38%
    Day's Range* 94.54 - 95.76
    52 wk Range 76.45-105.18
    Average Volume (10 days) 1.32M
    Average Volume (3 months) 35.87M
    Market Cap 119.05B
    P/E Ratio 14.19
    Shares Outstanding 1.25B
    Revenue 46.20B
    EPS 6.65
    Dividend (Yield %) 3.77479
    Beta 0.47
    Next Earnings Date Jul 28, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    May 30, 2023 94.07 -1.43 -1.50% 95.50 96.37 93.84
    May 29, 2023 98.66 0.52 0.53% 98.14 99.14 98.14
    May 26, 2023 99.17 0.77 0.78% 98.40 99.36 97.94
    May 25, 2023 98.30 -1.56 -1.56% 99.86 100.60 98.20
    May 24, 2023 100.56 0.14 0.14% 100.42 101.42 100.18
    May 23, 2023 100.72 0.92 0.92% 99.80 100.90 99.48
    May 22, 2023 100.08 -1.26 -1.24% 101.34 101.94 99.88
    May 19, 2023 101.42 1.79 1.80% 99.63 101.88 99.63
    May 18, 2023 99.64 0.65 0.66% 98.99 99.86 98.99
    May 17, 2023 98.60 -1.32 -1.32% 99.92 99.96 98.41
    May 16, 2023 100.10 0.99 1.00% 99.11 100.20 99.08
    May 15, 2023 99.54 -0.06 -0.06% 99.60 100.44 99.28
    May 12, 2023 99.04 -0.27 -0.27% 99.31 100.28 98.88
    May 11, 2023 98.97 -0.38 -0.38% 99.35 99.81 98.44
    May 10, 2023 98.29 -1.44 -1.44% 99.73 99.86 98.04
    May 9, 2023 100.48 0.28 0.28% 100.20 100.80 99.71
    May 8, 2023 100.00 -0.68 -0.68% 100.68 100.94 99.71
    May 5, 2023 101.38 2.20 2.22% 99.18 101.38 99.05
    May 4, 2023 99.10 0.97 0.99% 98.13 99.53 97.50
    May 3, 2023 97.70 0.86 0.89% 96.84 97.72 96.21

    Sanofi SA Events

    Time (UTC) Country Event
    Thursday, June 29, 2023

    Time (UTC)

    12:00

    Country

    FR

    Event

    Sanofi SA Vaccines Investor Event
    Sanofi SA Vaccines Investor Event

    Forecast

    -

    Previous

    -
    Friday, October 27, 2023

    Time (UTC)

    05:30

    Country

    FR

    Event

    Q3 2023 Sanofi SA Earnings Release
    Q3 2023 Sanofi SA Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 45389 39175 37369 37631 35677
    Revenue 45389 39175 37369 37631 35677
    Cost of Revenue, Total 13695 12255 12159 11979 11435
    Gross Profit 31694 26920 25210 25652 24242
    Total Operating Expense 34733 31049 23256 34580 31001
    Selling/General/Admin. Expenses, Total 10410 9457 9304 9777 9772
    Research & Development 6705 5689 5528 6017 5890
    Depreciation / Amortization 2140 1681 1774 2262 2264
    Unusual Expense (Income) -581 235 777 3966 1696
    Other Operating Expenses, Total 2391 1728 1220 817 61
    Operating Income 10656 8126 14113 3051 4676
    Interest Income (Expense), Net Non-Operating -167 -289 -263 -210 -273
    Other, Net -67 -39 -72 -89 2
    Net Income Before Taxes 10422 7798 13778 2752 4405
    Net Income After Taxes 8416 6240 11971 2631 3924
    Minority Interest -113 -56 -36 -31 -104
    Equity In Affiliates 68 39 359 255 499
    Net Income Before Extra. Items 8371 6223 12294 2855 4319
    Total Extraordinary Items 0 0 -101 -13
    Net Income 8371 6223 12294 2754 4306
    Income Available to Common Excl. Extra. Items 8371 6223 12294 2855 4319
    Income Available to Common Incl. Extra. Items 8371 6223 12294 2754 4306
    Dilution Adjustment
    Diluted Net Income 8371 6223 12294 2754 4306
    Diluted Weighted Average Shares 1256.9 1257.9 1260.1 1257.1 1255.2
    Diluted EPS Excluding Extraordinary Items 6.66004 4.94713 9.75637 2.2711 3.44089
    Dividends per Share - Common Stock Primary Issue 3.56 3.31263 3.2 3.15 3.07
    Diluted Normalized EPS 6.28676 5.09663 10.2921 5.28727 4.64452
    Interest Expense (Income) - Net Operating -27 4 -7506 -238 -117
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total revenue 10863 24594 13138 20795 10053
    Revenue 10863 24594 13138 20795 10053
    Cost of Revenue, Total 3079 7565 3831 6130 2880
    Gross Profit 7784 17029 9307 14665 7173
    Total Operating Expense 8400 17767 10414 16966 7656
    Selling/General/Admin. Expenses, Total 2607 5539 2644 4953 2379
    Research & Development 1563 3559 1736 3147 1489
    Depreciation / Amortization 489 1143 460 910 449
    Unusual Expense (Income) 343 231 1955 1021 198
    Other Operating Expenses, Total 304 -226 -180 788 265
    Operating Income 2463 6827 2724 3829 2397
    Interest Income (Expense), Net Non-Operating -7 -62 -51 -135 -78
    Net Income Before Taxes 2456 6748 2673 3674 2319
    Net Income After Taxes 1997 5237 2072 3179 1987
    Minority Interest -14 -60 -3 -53 -8
    Equity In Affiliates 12 10 7 58 30
    Net Income Before Extra. Items 1995 5187 2076 3184 2009
    Net Income 1995 5187 2076 3184 2009
    Income Available to Common Excl. Extra. Items 1995 5187 2076 3184 2009
    Income Available to Common Incl. Extra. Items 1995 5187 2076 3184 2009
    Diluted Net Income 1995 5187 2076 3184 2009
    Diluted Weighted Average Shares 1249.3 1258.5 1253.5 1255.3 1249.2
    Diluted EPS Excluding Extraordinary Items 1.59689 4.12157 1.65616 2.53645 1.60823
    Dividends per Share - Common Stock Primary Issue 0 3.56 0 0 0
    Diluted Normalized EPS 1.82014 4.26402 2.86513 3.24021 1.74404
    Interest Expense (Income) - Net Operating 15 -44 -32 17 -4
    Other, Net -17 -20
    Total Extraordinary Items
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 34026 30564 33703 28611 24579
    Cash and Short Term Investments 13400 11152 14815 9853 7124
    Cash 1385 1358 1144 701 661
    Cash & Equivalents 11351 8740 12771 8726 6264
    Short Term Investments 664 1054 900 426 199
    Total Receivables, Net 10746 9787 9953 10083 9345
    Accounts Receivable - Trade, Net 8424 7568 7491 7937 7260
    Total Inventory 8960 8715 8352 7994 7477
    Prepaid Expenses 714 615 525 493 469
    Other Current Assets, Total 206 295 58 188 164
    Total Assets 126722 120242 114413 112630 111408
    Property/Plant/Equipment, Total - Net 11684 11976 10563 11017 9651
    Property/Plant/Equipment, Total - Gross 26796 27555 24880 25151 22697
    Accumulated Depreciation, Total -15112 -15579 -14317 -14134 -13046
    Goodwill, Net 49892 48056 44364 44519 44235
    Intangibles, Net 21640 21407 18341 16509 21889
    Long Term Investments 2765 2425 2129 5303 5550
    Note Receivable - Long Term 452 485 537 521 746
    Other Long Term Assets, Total 6263 5329 4776 6150 4758
    Total Current Liabilities 23964 21295 19248 20381 17376
    Accounts Payable 6813 6180 5295 5313 5041
    Accrued Expenses 2158 2126 2042 1978 1989
    Notes Payable/Short Term Debt 168 189 285 305 249
    Current Port. of LT Debt/Capital Leases 4287 3263 2714 4508 2364
    Other Current Liabilities, Total 10538 9537 8912 8277 7733
    Total Liabilities 51938 51561 51307 53574 52532
    Total Long Term Debt 17047 19015 20725 21168 22071
    Long Term Debt 15143 17176 19794 20181 22053
    Capital Lease Obligations 1904 1839 931 987 18
    Deferred Income Tax 1841 1617 1770 2294 3414
    Minority Interest 368 350 146 174 159
    Other Liabilities, Total 8718 9284 9418 9557 9512
    Total Equity 74784 68681 63106 59056 58876
    Common Stock 2522 2527 2518 2508 2495
    Additional Paid-In Capital 66859 63545 60511 52049 53106
    Treasury Stock - Common -706 -939 -705 -9 -153
    Other Equity, Total 6109 3548 782 4508 3428
    Total Liabilities & Shareholders’ Equity 126722 120242 114413 112630 111408
    Total Common Shares Outstanding 1252.64 1252.54 1250.69 1253.83 1245.45
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 34026 28360
    Cash and Short Term Investments 12736 6899
    Cash & Equivalents 12736 6899
    Total Receivables, Net 8798 8406
    Accounts Receivable - Trade, Net 8424 7868
    Total Inventory 8960 9366
    Other Current Assets, Total 3532 3689
    Total Assets 126722 121826
    Property/Plant/Equipment, Total - Net 11684 11642
    Goodwill, Net 49892 50555
    Intangibles, Net 21640 21978
    Long Term Investments 2765 2650
    Note Receivable - Long Term 452 641
    Other Long Term Assets, Total 6263 6000
    Total Current Liabilities 23964 22060
    Accounts Payable 6813 6558
    Notes Payable/Short Term Debt 168 149
    Current Port. of LT Debt/Capital Leases 4287 3145
    Other Current Liabilities, Total 12696 12208
    Total Liabilities 51938 50875
    Total Long Term Debt 17047 18134
    Long Term Debt 15143 16133
    Capital Lease Obligations 1904 2001
    Deferred Income Tax 1841 1550
    Minority Interest 368 353
    Other Liabilities, Total 8718 8778
    Total Equity 74784 70951
    Common Stock 2522 2531
    Additional Paid-In Capital 66859 555
    Retained Earnings (Accumulated Deficit) 61883
    Treasury Stock - Common -706 -1169
    Other Equity, Total 6109 7151
    Total Liabilities & Shareholders’ Equity 126722 121826
    Total Common Shares Outstanding 1252.64 1252
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 8371 6223 12294 2754 4306
    Cash From Operating Activities 10526 10522 7418 7715 5547
    Cash From Operating Activities 3420 3351 3671 7445 4279
    Deferred Taxes -578 -356 -221 -1772 -727
    Non-Cash Items 20 -105 -8001 -293 -1031
    Cash Taxes Paid 2452 1280 2051 1695 2058
    Cash Interest Paid 380 334 315 379 412
    Changes in Working Capital -707 1409 -325 -419 -1280
    Cash From Investing Activities -2075 -7298 3619 -1029 -12872
    Capital Expenditures -2201 -2043 -2083 -1787 -1977
    Other Investing Cash Flow Items, Total 126 -5255 5702 758 -10895
    Cash From Financing Activities -5821 -7056 -6485 -4193 3934
    Financing Cash Flow Items -99 -48 -44 -21 -91
    Total Cash Dividends Paid -4168 -4008 -3937 -3834 -3773
    Issuance (Retirement) of Stock, Net -309 -196 -619 153 -924
    Issuance (Retirement) of Debt, Net -1245 -2804 -1885 -491 8722
    Foreign Exchange Effects 8 15 -64 9 1
    Net Change in Cash 2638 -3817 4488 2502 -3390
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line 8371 3184
    Cash From Operating Activities 10526 3825
    Cash From Operating Activities 3420 1820
    Deferred Taxes -578 -404
    Non-Cash Items 20 267
    Cash Taxes Paid 2452 927
    Cash Interest Paid 380 162
    Changes in Working Capital -707 -1042
    Cash From Investing Activities -2075 -1459
    Capital Expenditures -2201 -974
    Other Investing Cash Flow Items, Total 126 -485
    Cash From Financing Activities -5821 -5605
    Financing Cash Flow Items -99 -69
    Total Cash Dividends Paid -4168 -4168
    Issuance (Retirement) of Stock, Net -309 -320
    Issuance (Retirement) of Debt, Net -1245 -1048
    Foreign Exchange Effects 8 40
    Net Change in Cash 2638 -3199
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    L'Oreal SA Corporation 9.3672 118227307 0 2023-01-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 7.3542 92820373 -109952 2022-12-01 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.6227 33101922 275247 2023-04-30 LOW
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 2.1046 26563280 1278355 2022-12-31 LOW
    Sanofi SA Employees Corporation 2.0112 25384441 -502060 2023-01-31 LOW
    Dodge & Cox Investment Advisor/Hedge Fund 1.9805 24996804 -38447917 2022-12-31 LOW
    Amundi Asset Management, SAS Investment Advisor/Hedge Fund 1.7093 21574287 -49732 2023-04-30 MED
    T. Rowe Price Associates, Inc. Investment Advisor 1.3742 17344626 -233 2022-12-01 LOW
    Fidelity International Investment Advisor 0.9794 12360920 -275605 2023-03-31 LOW
    BlackRock Advisors (UK) Limited Investment Advisor/Hedge Fund 0.9046 11416977 -61760 2023-04-30 LOW
    Mellon Investments Corporation Investment Advisor/Hedge Fund 0.8696 10976049 9625458 2022-11-30 LOW
    BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.7484 9446072 -3499 2023-04-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.687 8670792 69 2023-04-30 LOW
    Janus Henderson Investors Investment Advisor/Hedge Fund 0.6778 8554174 -47826 2023-04-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 0.6157 7770600 31042 2023-03-31 LOW
    DWS Investment GmbH Investment Advisor/Hedge Fund 0.576 7269728 20328 2023-04-30 LOW
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.5352 6755031 -165288 2023-03-31 LOW
    BNP Paribas Asset Management France SAS Investment Advisor/Hedge Fund 0.5247 6622974 93156 2023-04-30 LOW
    First Eagle Investment Management, L.L.C. Investment Advisor/Hedge Fund 0.5245 6620194 -1970 2023-03-31 LOW
    Schroder Investment Management Ltd. (SIM) Investment Advisor/Hedge Fund 0.4129 5211829 -127 2023-04-30 LOW

    Why choose Capital.com? Our numbers speak for themselves.

    Capital.com Group

    530K+

    Traders

    87K+

    Active clients monthly

    $46M+

    Monthly investing volume

    $31M+

    Withdrawn each month

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Profit/Loss

    Sanofi Company profile

    Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
    Industry: Pharmaceuticals (NEC)

    46 Avenue de la Grande Armée
    PARIS
    ILE-DE-FRANCE 75017
    FR

    Income Statement

    • Annual
    • Quarterly

    News

    Nvidia HQ in Santa Clara, California

    Nvidia’s 5-year stock forecast: Will the chipmaker remain at record highs?

    Nvidia has been the winner of the AI race, being the first chip-maker to hit a $1tn market cap. Will the growth continue?

    07:46, 31 May 2023
    Alphabet Inc and Google logos on a smartphone screen

    Google stock forecast 2023-2025

    What is the outlook for the tech giant, following a tumultuous 2022?

    18:02, 30 May 2023
    Benjamin Franklin’s face on a $100 bill

    USD forecast: DXY slides in risk-off market sentiment

    The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.

    16:10, 24 May 2023
    Oil wells pictured in an oil field, silhouetted against clouds

    Oil price forecast: Will WTI and Brent regain momentum in 2023?

    Discover the drivers behind Brent and WTI volatility and get insights from analyst predictions.

    11:38, 22 May 2023
    businessman using a mobile phone to check stock market data

    Weekly Roundup: Tech stocks lead the way

    US stocks push higher as risk appetite surges despite the uncertainty

    13:39, 19 May 2023
    Japanese yen currency

    USD/JPY continues to build higher towards 138

    USD/JPY advances towards the top of its ascending triangle as the US dollar moves higher

    11:50, 17 May 2023
    Gold bars on a black background with a diagram

    Gold price predictions for next 5 years: Will gold continue rising?

    The yellow metal reached near record-highs, yet will it maintain the momentum and for how long?

    07:50, 17 May 2023

    People also watch

    Oil - Crude

    67.55 Price
    -2.750% 1D Chg, %
    Long position overnight fee -0.0155%
    Short position overnight fee -0.0064%
    Overnight fee time 21:00 (UTC)
    Spread 0.03

    BTC/USD

    27,078.95 Price
    -2.510% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 60.00

    US100

    14,331.30 Price
    -0.190% 1D Chg, %
    Long position overnight fee -0.0255%
    Short position overnight fee 0.0032%
    Overnight fee time 21:00 (UTC)
    Spread 1.8

    XRP/USD

    0.51 Price
    -3.230% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.00397

    Still looking for a broker you can trust?

    Join the 530.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading